BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
See today's BioWorld
Home
» ERISA class action challenges U.S. drug pricing scheme
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ERISA class action challenges U.S. drug pricing scheme
Aug. 31, 2017
By
Mari Serebrov
No Comments
Amid all the political and industry pontificating and finger-pointing on ever-increasing U.S. drug prices, patients are turning to the courts for relief, using a class action aimed at pharmaceutical benefit managers (PBMs) as their pulpit of choice.
BioWorld